EHR Data Refine Risk Prediction for Post-PCI Readmission

This article originally appeared here.
Share this content:
EHR Data Refine Risk Prediction for Post-PCI Readmission
EHR Data Refine Risk Prediction for Post-PCI Readmission

WEDNESDAY, Aug. 19, 2015 (HealthDay News) -- Patient characteristics extracted from their electronic health records can be used to refine risk prediction for hospital readmission after percutaneous coronary intervention, according to a study published online Aug. 18 in Circulation: Cardiovascular Quality and Outcomes.

Jason H. Wasfy, M.D., M.Phil., from Massachusetts General Hospital in Boston, and colleagues matched readmitted to non-readmitted patients in a 1:2 ratio by risk of readmission in an effort to improve ability to predict 30-day readmission after percutaneous coronary intervention. Unstructured and structured data were extracted from the electronic health record for 888 readmitted patients and 1,776 non-readmitted patients.

The researchers found that cases and controls differed significantly with respect to interpreter (7.9 and 5.3 percent, respectively; P = 0.009), emergency department visits (1.12 and 0.77, respectively; P < 0.001), homelessness (3.2 and 1.6 percent, respectively; P = 0.007), anticoagulation (33.9 and 22.1 percent, respectively; P < 0.001), atrial fibrillation/flutter (32.7 and 28.9 percent, respectively; P = 0.045), presyncope/syncope (27.8 and 21.3 percent, respectively; P < 0.001), and anxiety (69.4 and 62.4 percent, respectively; P < 0.001) in univariate analyses. There were independent associations for anticoagulation, emergency department visits, and anxiety with readmission.

"These results have the potential to improve risk assessment for early readmission after percutaneous coronary intervention, and emphasize the role of unmeasured confounders in risk assessment," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical technology industries.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths